ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
68 746,99
0,32%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cingulate Inc (CINGW)

  7. Cingulate Inc (CINGW) Actualités

CINGW

Cingulate (CINGW)

Cingulate Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CINGW
DateHeureSourceTitreSymboleSociété
24/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CINGWCingulate Inc
23/05/202423h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CINGWCingulate Inc
21/05/202415h00GlobeNewswire Inc.FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHDNASDAQ:CINGWCingulate Inc
17/05/202423h01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CINGWCingulate Inc
13/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
08/05/202413h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CINGWCingulate Inc
08/05/202413h00GlobeNewswire Inc.Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
30/04/202411h45GlobeNewswire Inc.Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessNASDAQ:CINGWCingulate Inc
16/04/202423h00GlobeNewswire Inc.Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024NASDAQ:CINGWCingulate Inc
01/04/202414h00GlobeNewswire Inc.Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
19/03/202421h45GlobeNewswire Inc.Cingulate to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
06/03/202412h45GlobeNewswire Inc.Cingulate to Attend DCAT Week 2024 in New York CityNASDAQ:CINGWCingulate Inc
13/02/202412h45GlobeNewswire Inc.Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsNASDAQ:CINGWCingulate Inc
06/02/202422h15GlobeNewswire Inc.Cingulate Announces Closing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
02/02/202415h15GlobeNewswire Inc.Cingulate Announces Pricing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
29/01/202414h00GlobeNewswire Inc.Longtime Cingulate Controller Jennifer Callahan Promoted to CFONASDAQ:CINGWCingulate Inc
29/01/202412h45GlobeNewswire Inc.Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketNASDAQ:CINGWCingulate Inc
01/12/202315h00GlobeNewswire Inc.Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)NASDAQ:CINGWCingulate Inc
13/11/202322h15GlobeNewswire Inc.Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
17/10/202320h22GlobeNewswire Inc.Cingulate to Host CNS Key Opinion Leader Panel in New York CityNASDAQ:CINGWCingulate Inc
21/09/202319h30GlobeNewswire Inc.Cingulate Inc. to Present at the LD Micro Main Event XVINASDAQ:CINGWCingulate Inc
13/09/202322h15GlobeNewswire Inc.Cingulate Announces Closing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202315h22GlobeNewswire Inc.Cingulate Announces Pricing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202312h00GlobeNewswire Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
08/09/202322h31GlobeNewswire Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumNASDAQ:CINGWCingulate Inc
05/09/202314h00GlobeNewswire Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023NASDAQ:CINGWCingulate Inc
14/08/202322h15GlobeNewswire Inc.Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
11/07/202314h00GlobeNewswire Inc.Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
29/06/202314h00GlobeNewswire Inc.Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustNASDAQ:CINGWCingulate Inc
14/06/202321h45GlobeNewswire Inc.Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-VestNASDAQ:CINGWCingulate Inc
 Showing the most relevant articles for your search:NASDAQ:CINGW

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
EU
BNP
BNP Paribas
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
EU
CS
Axa
EU
DG
Vinci
EU
LR
Legrand
USI
USTECH100
US Tech 100
EU
RNO
Renault
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés